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10241. Introduction
Rheumatoid arthritis (RA) is a chronic inﬂammatory disease charac-
terized by chronic and erosive arthritis that mainly involves peripheral
joints [1,2]. RA affects activities of daily living, signiﬁcantly decreasing
the quality of life of affected patients. Comorbidity is a major issue in
this disorder [1]. Cardiovascular (CV) disease has been described as the
main cause of premature mortality [2–6] and sudden death in patients
with RA [7]. This is the result of a process of accelerated atherosclerosis
[8,9].
Traditional CV risk factors such as smoking, diabetesmellitus, hyper-
tension, dyslipidemia and obesity are independently associated with
the development of CV disease [10–13], subclinical atherosclerosis
[12–14], and increased risk of CV mortality in patients with RA [15].
Chronic inﬂammation also appears to play an important role in the de-
velopment of subclinical atherosclerosis and CV events in patients with
RA [12,16–19].
Adequate CV risk stratiﬁcation has special relevance in RA to
identify patients at risk of CV disease. However, current CV risk
screening and management strategies underestimate the actual CV
risk in RA [20]. Consequently, the search of markers that may help
to identify RA patients at high CV risk has become a priority in the
last years [21].
Non-invasive, reproducible and cheap clinical surrogates, such
as carotid ultrasonography, have been found to be excellent predic-
tors of future CV events [22,23]. Several studies have also revealed
the implication of a genetic component in the development of CV
disease in RA patients [19,24,25]. Moreover, serum levels of some
metabolic syndrome-related biomarkers, adipokines and bio-
markers of endothelial cell activation and inﬂammation have re-
cently been found useful for the prediction of CV disease in these
patients [26,27].An update of the current knowledge on these potential markers, es-
pecially focused on new genetic and serological biomarkers is shown in
this review.
2. CVburden inRA and clinical surrogatemarkers of CVdisease inRA
Patients with RA are at greater risk of developing CV events [4,6,28].
Patients with RA are at a 50% increased risk of CV mortality compared
with the general population [3]. Women with RA were found to have
more than 2-fold higher risk of developing myocardial infarction com-
pared with women without this pathology, even after adjusting for po-
tential CV risk factors [29].
Endothelial dysfunction is a systemic pathological state of the endo-
thelium described as an early step in the development of atherosclerosis
in RA [17]. In this sense, several mechanisms link systemic inﬂammation
to endothelial dysfunction in these patients [8,30]. Components of the
metabolic syndrome that are frequently observed in RA [31,32] such as
insulin resistance (IR) and dyslipidemia along with an increased oxida-
tive stress can promote per se this process [8,30]. On the other hand,
the oxidation of low-density lipoprotein (LDL) induces the production
of inﬂammatorymolecules by the endothelial cells [30]. Furthermore, cir-
culating cytokines, especially tumor necrosis factor (TNF)-α, stimulate
the diapedesis of monocytes across the endothelium and also reduce
the synthesis of nitric oxide (NO) by endothelial cells [8,30].
Endothelial dysfunctionmay be determined by an impaired ability of
the artery to dilate in response to physical and chemical stimuli, due to
a decreased release or increased breakdown of NO [33]. Additionally,
this process can be non-invasively determined by ﬂow mediated
endothelium-dependent (FMD) vasodilatation using high-sensitivity
brachial ultrasonography [17,34,35]. Endothelial dysfunction was ob-
served in both long-standing RA patients [36] and young RA patients
with low disease activity and without traditional CV risk factors [37].
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the vascular wall, phenomenon that can be detectable by an increased
carotid intima–media thickness (cIMT) [9,38] or by the presence of ca-
rotid plaques [39,40] (both assessed by carotid ultrasonography).
cIMT corresponds to the width of the vessel intima and media, which
consists of endothelium, connective tissue and smooth muscle and is
also the site of lipid deposition and plaque formation [41]. A meta-
analysis encompassing several population based studies has revealed
increased cIMT values in RA patients when compared with non-
rheumatic population [42]. Interestingly, as observed in the general
population, abnormally high values of cIMT (greater than 0.90 mm)
have been found to predict the development of CV events in patients
with RA after 5 years of follow-up [22]. Carotid plaque (deﬁned as a
focal protrusion in the lumen at least cIMT N 1.5 mm, protrusion at
least 50% greater than the surrounding cIMT, or arterial lumen
encroaching N0.5 mm in the accessible extracranial carotid tree [43])
has also been described to be an excellent predictor of future CV events
in RA [23]. In fact, a 2.5 increased risk of CV events among RA patients
with unilateral carotid plaques, and 4.3 among those with bilateral ca-
rotid plaques have been reported [23].
A good correlation between the assessment of endothelial function
by FMD and the presence of abnormally increased cIMT was observed
in RA patients with long disease duration [44].
Finally, besides studies aimed to determine the presence of function-
al or morphological atherosclerotic changes [45], other non-invasive
surrogate markers of CV disease, such as the pulse wave velocity to de-
termine the velocity at which the arterial pulse propagates, which is
used clinically as a measure of arterial stiffness hand has a strong corre-
lation with CV events and all-cause mortality in the general population
have been found useful in the assessment of CV disease in patients with
RA [46].
3. Genes and CV disease in RA
Different studies indicate that genetics plays an important role in the
development of CV disease in patients with RA. Most of these studies
were conducted by candidate genes strategy inwhich a speciﬁc polymor-
phism or a set of genetic variants within certain loci were genotyped.
These polymorphisms were selected according to their potential biologi-
cal function or the location in a region previously reported as associated
with disease susceptibility or severity. Overall, the result of these studies
supports the claim that the genetic component implicated in the develop-
ment of CV disease in RA is complex, probably the result of gene–gene in-
teractions modulated by environmental factors in which the speciﬁc role
of a single gene is small. A summary of the main studies addressing the
genetic inﬂuence in the risk of subclinical atherosclerosis and CV disease
in RA is summarized in Table 1.
3.1. Human leukocyte antigen (HLA) and related genes
HLA region includes a group of genes located in the chromosome 6
(6p21) that encode the most polymorphic human proteins, the class I
and class II antigen-presenting molecules [47]. Accordingly, HLA is the
main genetic factor implicated in inﬂammatory immune-mediated pa-
thologies, being associated with more diseases than any other region of
the human genome [47]. With respect to RA, HLA-DRB1 gene, especially
theHLA-DRB1*04 shared epitope (SE) alleles, is considered as a risk factor
for RA, not only regarding disease susceptibility but also for its implication
in the development of CV disease [19]. RA patients carrying 2 copies of the
SE exhibit approximately 2-fold increase in mortality due to CV events
[19,48], mainly from ischemic heart disease [49]. When speciﬁc SE geno-
types were analyzed, the HLA-DRB1*01/*04 combination seems to confer
the highest CV risk [19,48,49]. A relationship betweenHLA-DRB1 and sub-
clinical atherosclerosis in RA patients has also been demonstrated. In this
context,HLA-DRB1*0404was associatedwith endothelial dysfunction [36,
50] and with the presence of carotid plaques [51].HLA-II gene expression is transcriptionally regulated by class II tran-
scriptional activator (CIITA) [52]. This protein acts as a platform for the
assembly of various transcription factors to differentially regulate a
number of other genes (such as those that codify collagen, cathepsin
E, interleukin (IL)-4 and IL-10) [53] and, also, plays a crucial role in ath-
erosclerotic plaque development and complication [53]. This molecule
is encoded by MHC2TA gene and two genetic variants located in the
gene, rs3087456 (−168ANG) and rs4774 (+1614GNC, Gly500Ala),
were tested to establish their implication in the development of CV dis-
ease in RA. However, no relationship between each polymorphism eval-
uated individually or in combination conforming haplotypes and
clinical CV events or subclinical atherosclerosis was disclosed [54].3.2. TNF superfamily genes
TNF superfamily cytokines are a group of proteins that activates the
nuclear factor-κB (NF-κB) and mitogen activated protein (MAP) kinase
signaling pathways [55]. Among them, the potential role of TNF-α, TNF-
β, OPG andCD40-CD40L binding in the development of CVdisease in RA
patients has been evaluated [24,56–60].
TNF-α is a cytokine produced essentially by activated macrophages,
although it can be produced by many other cell types [55]. This protein
is involved in systemic inﬂammation, acute phase response and also, in
the pathogenesis of a large number of human diseases, including RA
[61]. A relevant role of TNF-α in atherosclerosis has also been postulated
[62]. TNFA genetic variants, mainly TNFA rs1800629 (located at TNFA
promoter), have been proposed as risk factors for autoimmune diseases
[63]. In particular, themutant A allele of TNFA rs1800629 has been relat-
ed to a higher predisposition to CV complications in those RA patients
carrying at least a copy of the rheumatoid SE [24]. The implication of an-
other TNFA genetic variant in the risk of CV disease in RA, rs1799964,
was also evaluated. Although a relationship between rs1799964 poly-
morphism with a more pro-atherogenic lipid proﬁle was described, no
association of this polymorphism with CV events was found [56].
TNF-β or lymphotoxin α (LTA), a cytokine produced by T-helper 1
type T-cells, is best known for its role in the development of lymphoid
organs [64]. This protein also induces vascular endothelial cells to
change their surface adhesion molecules to allow phagocytic cells to
bind to them and, in consequence, is implicated in the early stages of
the vascular inﬂammatory process [65]. In addition, peripheral TNF-β
levels showed a correlation with plaque size in mice models [66]. Fol-
lowing these observations, the potential role of a LTA genetic variant
(rs909253 252ANG) in the increased CV risk observed in RA patients
was assessed [57]. Interestingly, a relationship between the 252GGmu-
tant genotype and a higher risk of myocardial infarction was disclosed
[57].
A well-knownmember of the TNF receptor superfamily that plays a
central role in bone remodeling is osteoprotegerin (OPG) [67,68]. This
molecule has been associated with increased risk of atherosclerotic dis-
ease in the general population [69]. The OPG human gene is affected by
genetic polymorphisms with functional consequences on CV disease
and bone metabolism [70,71]. Particularly, OPG rs2073617, OPG
rs2073618 and OPG rs3134069 (located in 5´UTR region, exon 1 and
promoter region, respectively) have been related to atherosclerosis
and risk of cerebrovascular disease in non-rheumatic individuals [72,
73]. OPG rs3134063 (genetic variant in complete linkage disequilibrium
with rs2073617) as well as OPG rs2073618 and OPG rs3134069 were
tested to determine their inﬂuence in the risk of CV disease of patients
with RA [58]. The result of this assessment revealed that anti-cyclic
citrullinated peptide (anti-CCP) antibody-negative RA patientswho car-
ried the OPG rs2073618GG genotype had a lower risk of developing ce-
rebrovascular complications [58]. Additionally, a protective effect of the
OPG CGA haplotype (that carries theOPG rs2073618G allele) against the
risk of cerebrovascular events in the subgroup of RA patients who were
anti-CCP antibody-negative was found [58].
Table 1
Genetic association studies in CV disease in patients with RA.
Gene CV variable analyzed Results
HLA-DRB1 -CV mortality, CV events -*0404 ↑ CV events and mortality [19]. 2 copies of the SE are related to higher CV
mortality [19,48], mainly IHD [49].*01/04 offers the highest CV risk [19,48,49].
-FMD -*0404 ↓ FMD [36,50].
-FMD, cIMT, carotid plaques -*0404 ↑carotid plaques [51].
MHC2TA -CV events, FMD, cIMT -No association of rs3087456 and rs4774 [54].
TNFA -CV events, FMD, cIMT -rs1800629A mutant allele ↑ CV complications in patients carrying at least a copy of
the SE [24].
-Atherogenic measures -rs1799964C mutant allele ↑ pro-atherogenic lipid proﬁle [56].
LTA -CV events -rs909253GG mutant genotype ↑MI risk [57].
OPG -CV events -Protective effect of CGA haplotype against CVA in anti-CCP negative patients [58].
CD40 -ATM -rs1535045 and rs3765459 are related to CV disease [59].
-CV events, FMD, cIMT -rs1535045T mutant allele ↓ cIMT. No association of rs1883832 and rs4810485 [60].
CD40L -CV events, FMD, cIMT -No association of rs3092952 and rs3092920 [60].
IL6 -CV disease -rs1800795C mutant allele ↑ the CV risk [76].
-FMD -rs1800795GG genotype ↓ FMD [77].
-CV events -No association of rs1800795, rs2069827 and rs2069840 [78].
IL6R -CV events, FMD, cIMT -No association of rs2228145 [82].
IL6ST -CV events, FMD, cIMT -No association of rs2228044 [82].
IFN-ϒ -CV events, FMD, cIMT, carotid plaques -No association of rs2430561 [83].
IRF5 -CV events -Protective effect of rs2004640GG, rs10954213GG and GTG haplotype against CV events
[92].
JAK3 -CV events, cIMT, carotid plaques -No association of rs3212780 and rs3212752 [95].
IL33 -cIMT -Protective effect of rs3939286T mutant allele. No association of rs7025417 and
rs7044343 [103].
IL1RL1 -cIMT -No association of rs2058660, rs2310173, rs13015714 [103].
NFKB1 -CV events -NFKB1–94 (rs28362491) deletion/deletion ↑ CV risk [25].
TGFB1 -CV events -rs1800470TC genotype and smoking combination ↑ IHD and MI [108].
SMAD3 -CV events -rs17228212Cmutant allele ↓ CVA risk and subclinical ATS in anti-CCP negative patients
[118].
CCR5 -CV events, FMD, cIMT -Carriers of CCR5Δ32 deletion showed ↑ FMD [119].
MIF -CV events -No association of−173 and -794 [120,121].
-FMD, cIMT -No association of−173 [120].
ADIPOQ -CV events, FMD, cIMT -No association of rs266729 and rs1501299 [150].
LEP -CV events, FMD, cIMT -No association of rs2167270 [157].
RETN -CV events, FMD, cIMT -No association of rs1862513 [165].
NAMPT -CV events, FMD, cIMT -No association of rs9770242 and rs59744560 [170].
PON1 -Carotid plaques -rs662RR mutant genotype ↓ carotid plaques [179].
-cIMT, carotid plaques -No association of rs662 [180].
-CV disease -Anti-HDL antibodies may be pivotal players in the link between PON1 and CV disease
[181].
VDR -Carotid plaques -↑ carotid plaques frequency in patients who carried the GATG haplotype [186].
VEGFA -CV events, FMD, cIMT -No association of rs2010963 and rs1570360 [199].
NOS -CV events -Interaction between NOS and HLA-DRB1 ↑ CV events risk [209].
TLR4 -CV events, FMD, cIMT -No association of rs4986790 [225].
CARD8 -CV events, cIMT, carotid plaques -No association of rs2043211 [229].
MTHFR -CV events, FMD -1298C mutant allele ↑ CV events risk (after 5 and 10 years of follow-up) and ↓ FMD.
No association of C677T [235].
-IHD -↓ MTHFR expression in IHD [236].
MSRA -CV events -rs10903323A mutant allele ↑ CV events (mainly IHD) [239].
GHSR -CV events, FMD, cIMT -No association of rs509035, rs512692 and rs2922126 [245].
ACP1 -CV events -rs11553742T mutant allele and ACP1*C haplotype ↑ CV events. No association of
rs10167992 and rs3828329 [253].
PTPN22 -CV events, FMD, cIMT -No association of rs2476601 [261].
TRAF1/C5 -CV events, FMD, cIMT -No association of rs10818488 [261].
-CV mortality -No association of rs10818488 [262].
STAT4 -CV events, FMD, cIMT -No association of rs7574865 [261].
PIK3CG -CV events, cIMT, carotid plaques -No association of rs17398575 [264].
EDNRA -CV events, cIMT, carotid plaques -No association of rs1878406 [264].
ABO -CV events, cIMT, carotid plaques -No association of rs579459 [264].
-CV events -No association of rs579459 [266].
PPAP2B -CV events, cIMT, carotid plaques -No association of rs17114036 [264].
-CV events -No association of rs17114036 [266].
ADAMTS7 -CV events, cIMT, carotid plaques -No association of rs3825807 [264].
-CV events -No association of rs3825807 [266].
PCSK9 -CV events -No association of rs11206510 [266].
WDR12 -CV events -No association of rs6725887 [266].
MRAS -CV events -No association of rs2306374 [266].
LPA -CV events -No association of rs3798220 [266].
MRPS6 -CV events -No association of rs9982601 [266].
ANKS1A -CV events -No association of rs17609940 [266].
TCF21 -CV events -No association of rs12190287 [266].
CYP17A1-CNNM2-NT5C2 -CV events -No association of rs12413409 [266].
HHIPL1 -CV events -No association of rs2895811 [266].
SMG6-SRR -CV events -No association of rs216172 [266].
RASD1-SMCR3-PEMT -CV events -No association of rs12936587 [266].
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Table 1 (continued)
Gene CV variable analyzed Results
UBE2Z-GIP-ATP5G1-SNF8 -CV events -No association of rs46522 [266].
PSRC1- CELSR2- SORT1 -FMD -rs599839G mutant allele ↓ FMD [268].
ZC3HC1 -cIMT -rs11556924T mutant allele ↑ cIMT values [267].
MIA3 -CV events -No association of rs17465637 in UK patients [266].
-CV events, FMD, cIMT, carotid plaques -rs17465637A allele is related to CV events risk in dyslipidemic Spanish patients [269].
ZNF259-APOA5-A4-C3-A1 -CV events -No association of rs964184 in UK patients [266].
-CV events -rs964184G mutant allele ↑CV events in Spanish patients [271].
CXCL12 -CV events -rs1746048T mutant allele ↑ CV events in UK patients [266].
-CV events, FMD, cIMT -No association of rs1746048 in Spanish patients [270].
CV: cardiovascular; RA: rheumatoid arthritis; HLA: Human leukocyte antigen; SE: shared epitope; IHD: ischaemic heart disease; FMD: endothelial dependent vasodilation; cIMT: carotid
intima–media thickness;MHC2TA: class II major histocompatibility complex transactivator; TNFA: tumor necrosis factor alpha, LTA: lymphotoxin alpha;MI: myocardial infarction; OPG: oste-
oprotegerin;CVA: cerebrovascular accident; anti-CCP antibodies: anti-cyclic citrullinated peptide antibodies; ATM: atherothromboticmanifestations; CD40L: CD40 ligand; IL6: interleukin 6;
IL6R: interleukin 6 receptor; IL6ST: interleukin 6 Signal Transducer; IFN-ϒ: interferon-gamma; IRF5: interferon regulatory factor 5; JAK3: janus kinase 3; IL33: interleukin 33; IL1RL1: interleukin 1
receptor-like 1; NFKB1: factor nuclear NF-kappa-B; TGFB1: transforming growth factor beta 1; ATS: atherosclerosis; CCR5: C-C chemokine receptor type 5; MIF: macrophage migration inhibitory
factor; ADIPOQ: adiponectin; LEP: leptin; RETN: resistin; NAMPT: nicotinamide phosphoribosyltransferase; PON1: paraoxonase 1; HDL: high-density lipoproteins; VDR: vitamin D receptor;
VEGFA: vascular endothelial growth factor A; NOS: nitric oxide synthase; TLR4: toll-like receptor 4; CARD8: caspase recruitment domain family member 8; MTHFR: methylenetetrahydrofolate re-
ductase; MSRA: methionine sulfoxide reductase A; GHSR: hormone secretagogue receptor; ACP1: acid phosphatase 1; PTPN22: protein tyrosine phosphatase non-Receptor type 22; TRAF1/C5: TNF
receptor associated factor 1/complement component 5; STAT4: signal transducer and activator of transcription 4; PIK3CG: phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit
gamma; EDNRA: endothelin receptor type A; ABO: histo-blood group ABO system transferase; PPAP2B: phosphatidic acid phosphatase type 2B; ADAMTS7: metallopeptidase with thrombospondin
type 1 motif 7; PCSK9: proprotein convertase subtilisin/kexin type 9; WDR12:WD repeat domain 12; MRAS: muscle RAS oncogene homolog; LPA: lipoprotein(a); MRPS6: mitochondrial ribosomal
protein S6; ANKS1A: ankyrin repeat and sterile alpha motif domain containing 1A; TCF21: Transcription Factor 21; CYP17A1-CNNM2-NT5C2: cytochrome P450 family 17 subfamily A member 1-
cyclin and CBS domain divalent metal cation transport mediator 2-5′-nucleotidase, cytosolic II; HHIPL1: hedgehog interacting protein-like 1; SMG6-SRR: SMG6 nonsense mediated mRNA decay
factor- Serine racemase; RASD1-SMCR3-PEMT: RAS, dexamethasone-induced 1-Smith–Magenis syndrome chromosome region candidate 3-phosphatidylethanolamine N-methyltransferase;
UBE2Z-GIP-ATP5G1-SNF8: ubiquitin conjugating enzyme E2 Z-gastric inhibitory polypeptide-ATP synthase, H+ transporting, mitochondrial Fo complex subunit C1 (subunit 9)-SNF8, ESCRT-II
complex subunit; PSRC1- CELSR2- SORT1: proline/serine-rich coiled-coil 1-cadherin EGF LAG seven-pass G-type receptor 2-sortilin 1; ZC3HC1: zinc ﬁnger C3HC-type containing 1;MIA3:melanoma
inhibitory activity family member 3; ZNF259-APOA5-A4-C3-A1: zinc ﬁnger protein 259-apolipoprotein A-V-IV-C-III-A-I; CXCL12: C-X-C motif chemokine ligand 12.
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interactions that also mediates pro-atherogenic biological responses
(expression of cytokines, chemokines, growth factors, matrix metal-
loproteinases) [55]. Several polymorphisms located both in CD40
and CD40L genes were evaluated according to the development of
CV disease in RA patients [59,60]. Regarding CD40, the rs3765459
polymorphism was found to be a genetic variant associated with
CV events [59] whereas the CD40 rs1535045 variant was associated
with CV events [59] and subclinical atherosclerosis (an assessment
by carotid ultrasound disclosed association with cIMT) [60]. Howev-
er, neither CD40 rs1883832 nor CD40 rs4810485 polymorphisms
were found to be associated with CV events or subclinical atheroscle-
rosis in RA [60]. Regarding CD40L, no association was observed when
CD40L rs3092952 and CD40L rs3092920 polymorphisms were
assessed for the presence of CV events or subclinical atherosclerosis
in patients with RA [60].
3.3. Cytokines and related genes
Cytokines constitute a broad category of small proteins that regulate
fundamental biological processes including body growth, adiposity, and
hematopoiesis.
One of the most relevant pro-inﬂammatory cytokines is the IL-6.
This pleiotropic protein is produced bydifferent cells (monocytes, endo-
thelial cells, ﬁbroblasts and activated T lymphocytes) [74] and is essen-
tial in adaptive immunity [75]. Besides, this molecule also acts in the
innate immune response contributing to the systemic effects of inﬂam-
mation [75]. The potential association between IL6 gene and the devel-
opment of CV disease in RA has been tested by several authors with
apparently contradictory results [76–78]. With respect to this, a genetic
variant located in the 5′ ﬂanking region at position −174 (GNC;
rs1800795) was associated with higher risk of CV disease as well as an
increased endothelial dysfunction in a relatively small cohort of British
[76] and Spanish [77] RA patients, respectively. However, when
assessed in a larger cohort of patients in whom the major variability of
the IL6 gene was covered by tagging, no association between IL6 -174
rs1800795 and CV events was found [78]. It was also the case for anoth-
er two IL6 polymorphisms (rs2069827 and rs2069840) [78].
Both IL-6 levels and functions seem to be partially controlled by its
receptor [79]. In this sense, IL-6 receptor is a protein complex consistingof an IL-6 receptor subunit (IL6R) and IL-6 signal transducer Glycopro-
tein 130 (also called IL-6ST). A study performed in a large cohort of
Spanish RA patients evaluated the inﬂuence of the IL6R rs2228145
(that alters IL6R levels [80]) and IL6ST rs2228044 (related tomyocardial
infarction in a hypertensive population [81]) in the risk of CV disease
[82]. However, the results derived from this study revealed a lack of as-
sociation between these two genetic variants and CV events or endothe-
lial dysfunction in RA [82].
Due to the association of themean values of C-reactive protein (CRP)
in long-standing RA patients with the presence of subclinical athero-
sclerosis [18], CV events and CV mortality [19], our group has set up a
study to determine the potential inﬂuence of CRP gene polymorphisms
in the risk of CVdisease in patientswithRA. For this purpose, 3 CRPpoly-
morphisms (rs1417938, rs1800947, rs1205) selected by tagging and 9
genetic variants (HNF1A, LEPR, GCKR, NLRP3, IL1F10, PPP1R3B, ASCL1,
HNF4A and SALL1) related to serum CRP levels in non-rheumatic Cauca-
sians have been genotyped by TaqMan assays in a total of 2,313 Spanish
RA patients. However, unpublished preliminary observations suggest
that there is no association between these CRP serum level-related ge-
netic variants and the presence of subclinical atherosclerosis or CV
events in patients with RA (unpublished data).
Interferon gamma (IFN-ϒ) is a pleiotropic cytokine member of the
type II class of interferons involved in innate and adaptive responses
[83] that also plays a relevant role in atherosclerosis and plaque disrup-
tion (by enhancing expression of adhesion molecules on endothelial
cells) [84]. This molecule recruits macrophages and T cells into the
plaque, contributing to the production of reactive oxygen species,
inhibiting collagen production, stimulating matrix metalloproteinases,
and inducing tissue factors expression [6,85,86]. Taking into account
all these considerations, we studied the potential implication of the
functional IFNG rs2430561 polymorphism in the risk of CV disease in
RA [83]. However, no association of IFNG rs2430561 with CV events or
subclinical atherosclerosis was observed in patients with RA [83].
Type I IFN gene transcription is regulated by a molecule termed in-
terferon regulatory factor 5 (IRF5) [87,88] and, therefore, this protein
is critical for the production of pro-inﬂammatory cytokines [89]. Fur-
thermore, IRF5 acts as a molecular switch that controls inﬂammatory
mechanismsmediated bymacrophage cells [89]. Some genetic variants
located in IRF5 have been proposed as essential players in the develop-
ment of rheumatic diseases [90,91]. Particularly, IRF5 rs2070197, IRF5
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ciated with these inﬂammatory disorders. Regarding the development
of CV disease in RA, a recent study has shown a protective effect of
both the IRF5 rs2004640GG and the IRF5 rs10954213GG genotypes
against the risk of CV events [92]. Additionally, when IRF5 rs2070197,
IRF5 rs2004640 and IRF5 rs10954213 were analyzed together, a protec-
tive effect of the GTG haplotype in the development of CV events in pa-
tients with RA was also found [92].
Most ILs (such as IL-6), IFNs and colony-stimulating factor (CSFs)
mediate their effects through the Janus kinase (JAK)-signal transducers
and activators of transcription (STAT) pathway [55]. Among them, JAK3
is a member of the JAK family protein which associates with the com-
mon γ (γc) chain [93]. JAK3 has limited tissue expression and its only
meaningful biological function is restricted to immune cells [55]. A rela-
tionship between JAK3 genetic variants and inﬂammatory disorders, in-
cluding the development of CV events in incident dialysis patients, was
reported [94]. However, we could not ﬁnd an association of 2 genetic
JAK3 variants, JAK3 rs3212780 and JAK3 rs3212752, with the risk of CV
disease in Spanish individuals with RA [95].
Another recently characterized pro-inﬂammatory cytokine that be-
longs to the IL-1 family is the IL-33 [96]. This molecule exerts its biolog-
ical function by interacting with its receptor (IL-1 receptor like 1 (IL-
1RL1)) and co-receptor (IL-1 receptor accessory protein (IL-1RAcP)).
The IL-33-IL-1RL1 bindingmediates relevant immunomodulatory func-
tions [96]. Regarding RA, an association between baseline detectable IL-
33 concentrations and the development of severe subclinical athero-
sclerosis was described [97]. Because of that, we analyzed the potential
inﬂuence of the IL33 rs3939286, IL33 rs7025417, IL33 rs7044343, IL1RL1
rs2058660, IL1RL1 rs2310173 and IL1RL1 rs13015714 polymorphisms,
which were described to be associated with several inﬂammatory dis-
eases [98–102], on the risk of CV disease in RA [103]. Interestingly, we
disclosed a potential protective effect of themutant IL33 rs3939286T al-
lele in the risk of subclinical atherosclerosis in patients with RA [103].
IL-1 (including IL-33) and TNF family members activate NF-kB sig-
naling pathway [55]. The latter plays a central role in inﬂammation
through the regulation of genes encoding pro-inﬂammatory cytokines,
adhesion molecules, chemokines, growth factors, and inducible en-
zymes such as inducible nitric oxide synthase [104]. Because of that,
the inappropriate activation of NF-kB predisposes to the development
of a variety of human diseases and pathologic conditions [105,106].
With respect to this, the NFKB1 −94 insertion/deletion ATTG
(rs28362491) promoter polymorphism, that shows functional effects
on the transcription of NFKB1, has been related to several immune-
mediated disorders [107]. In keeping with that, an association between
this genetic variant (speciﬁcally theNFKB1−94deletion/deletion geno-
type) and a higher risk of CV events in RA patients was found [25].
Transforming growth factor beta 1 (TGF-β1) is a multifunctional cy-
tokine belonging to the TGF-β superfamily implicated in themodulation
of both immunity and inﬂammation [108]. The role of TGF-β1 in the
pathogenesis of atherosclerosis has long been the subject of debate
[109,110]. Inhibition of endogenous TGF-β signaling favors the develop-
ment of atherosclerotic lesions [109]. However, a pro-atherogenic role
of TGF-β1 is also suspected since it is able to promote ﬁbrosis and to in-
hibit endothelial regeneration [110]. Regarding these observations,
some authors have analyzed whether variations in the TGFB1 gene
could be involved in the development of CV disease in RA patients
[108]. For this purpose, TGFB1-509 C/T (rs1800469, in the promoter re-
gion), +868 T/C (rs1800470, in exon 1) and +913 G/C (rs1800471, in
exon 1) were evaluated [108]. The result of this assessment yielded
that the combination of TGFB1 rs1800470TC genotype and smoking
habit was associatedwith a higher risk of CV events (especially ischemic
heart disease and myocardial infarction) [108].
TGF-β superfamily cytokines mediate their effects by activating sig-
naling proteins of the SMAD family [55]. Thesemolecules are intracellu-
lar proteins that transduce extracellular signals to the nucleus where
they activate downstream gene transcription [111–113]. Among them,SMAD3 has an essential role in downregulating T-cells and increasing
regulatory T-cells differentiation [114]. Besides, SMAD3 expression has
been found in human plaques, mainly in macrophages of ﬁbro-fatty le-
sions and in smooth muscle cells of ﬁbrous caps [115]. SMAD3 gene has
been implicated in different immune-mediated disorders [116,117]. In
this regard, the SMAD3 rs17228212 genetic variant (themutant C allele)
was associated with a lower risk for cerebrovascular accidents and less
severe subclinical atherosclerosis in patients with RA who were nega-
tive for anti-CCP antibodies [118].
3.4. Chemokines genes
Chemokines are a family of small cytokines that have the ability to
induce directed chemotaxis in nearby responsive cells [55]. These mol-
ecules are especially important in the regulation of inﬂammatory and
immune responses and have crucial functions in controlling both innate
and adaptive immunity [55]. Because of that, the inﬂuence of these pro-
teins in the CV risk associated with RA was evaluated by different au-
thors [119–121].
CCR5 (C-C chemokine receptor type 5) is a protein located on the
surface of white blood cells that is involved in the immune response
as it acts as a receptor for chemokines. Additionally, a potential pro-
inﬂammatory effect of this molecule in both RA pathogenesis and ath-
erosclerosis has been proposed [122]. The implication of the CCR5Δ32
rs333 polymorphism (deﬁned by a 32-bp deletion that leads to a trun-
cated nonfunctional receptor [123]) has been studied in different dis-
eases. It is known that in individuals who are homozygous for this
deletion CCR5 is absent from the cell surface [124] whereas heterozy-
gous individuals express 20% to 30% of the CCR5 levels observed in
wild-type individuals [125]. Although the role of this genetic variant
in both the development of CV disease [126–130] and RA pathogenesis
[131–133] has generated contradictory results, a study in Spanish pa-
tients with RA suggested an implication of this polymorphism with CV
disease [119]. In this regard, carriers of the CCR5Δ32 deletion showed
higher FMD values than the remaining patients (7.03% ± 6.61% versus
5.51%± 4.66%). This differencewas statistically signiﬁcant when analy-
sis of covariance was performed (P = 0.024). Because of that, these re-
sults speak in favor of a protective effect of CCR5Δ32 rs333 against the
development of endothelial dysfunction in patients with RA [119].
Themacrophagemigration inhibitory factor (MIF) is a predominant-
lymacrophage-derived cytokine, which has been reported to contribute
to the development of CV disease [134]. Alternatively, MIF displays
chemokine-like functions and acts as amajor regulator of inﬂammatory
cell recruitment and atherogenesis [135]. TwoMIF polymorphisms pre-
viously related to higher plasmaMIF levels (a tetra-nucleotide repeat el-
ement starting at position −794 [CATT5–8] and a single-nucleotide
polymorphism at position -173 [G/C]) were tested to determine a po-
tential association with CV disease in RA [120,121]. However, neither
of these genetic variants was associated with the development of CV
events [120,121]. In addition, no association of theMIF-173 with sub-
clinical atherosclerosis, studied by the assessment of cIMT and FMD
values, was found [120].
3.5. Adipokines genes
The term adipokines is referred to a speciﬁc group of immunemedi-
ator proteins secreted by the adipose tissue [136]. These molecules in-
ﬂuence metabolic processes such as glucose and lipid metabolism
[137] and exert potentmodulatory actions on target tissues and cells in-
volved in rheumatic diseases [138,139].
Among these molecules is adiponectin. This adipokine is secreted by
adipocytes and circulates in the blood in large amounts and constitutes
approximately 0.01% of the total plasma proteins [140]. Adiponectin in-
creases fatty acid oxidation and reduces the synthesis of glucose in the
liver and other tissues [141]. Several studies have revealed that
adiponectin circulating levels inversely correlate with adiposity [142,
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tion was independently and negatively correlated with circulating
adiponectin concentrations whereas low adiponectin levels clustered
with metabolic syndrome (MetS) features that reportedly contribute
to atherogenesis in RA [143]. These ﬁndings suggest that this adipokine
may exert a protective function against CV disease and obesity. Interest-
ingly,ADIPOQ rs266729 andADIPOQ rs1501299 gene variants have been
found associated with CV disease in non-rheumatic individuals
[144–149]. Taking into account these considerations, these two ADIPOQ
gene variants were tested in patients with RA. However, no association
with CV events or subclinical atherosclerosis was observed [150].
Leptin is another adipokine mainly produced by adipocytes [136,
140] with a crucial role in body weight regulation by inhibiting food
intake and stimulating energy expenditure [151]. This protein also
induces the production of pro-inﬂammatory cytokines such as IL-6,
IL-12, and TNF-α by monocytes and macrophages [152] while it sup-
presses the production of IL-4 and anti-inﬂammatory cytokines [153].
In patients with RA undergoing anti-TNF therapy, circulating leptin
levels constituted a manifestation of adiposity [154]. In this regard, a
strong association between leptin serum levels and body mass index
was observed in RA patients with severe disease [154]. Since a genetic
variant located in LEP gene (LEP rs2167270) was proposed as a relevant
signal involved in the leptin levels [155] and obesity [156], García-
Bermúdez et al. analyzed the potential association between this poly-
morphism and the development of CV disease in RA [157]. However,
no signiﬁcant association was observed with CV events or subclinical
atherosclerosis (evaluated by cIMT assessment and FMD studies) [157].
Another adipocyte-derived mediator that plays an important role in
inﬂammation [136,158] is a protein called resistin. Although this mole-
cule can be detected at very low levels in human adipose tissue, it is
mainly found in peripheral blood mononuclear cells [159]. Resistin has
been found to be up-regulated by some cytokines such as TNF-α and
IL-6 [160] and has been proposed as an importantmolecule in NF-κB ac-
tivation and cytokine production [161]. A signiﬁcant association be-
tween the mean erythrocyte sedimentation rate (ESR) and CRP from
disease diagnosis and ESR, CRP and platelet count at the time of the
study and Resistin levels in patients with RA refractory to conventional
disease-modifying anti-rheumatic drugs that required biologic therapy
was observed [162]. Interestingly, a polymorphism located at the RETN
gene promoter (RETN rs1862513) was found associated with a higher
risk of cerebrovascular disease in patients with type 2 diabetes mellitus
[163,164]. Based on theseﬁndings, this genetic variantwas tested for CV
risk in patients with RA. However, no association between RETN
rs1862513 and CV events or subclinical atherosclerosiswas found in pa-
tients with RA [165].
Finally, visfatin is an insulin-mimetic adipokine with ubiquitous ex-
pression that has also been associated with inﬂammation [136,166].
This adipokine correlates with visceral fat [167] and has been described
as an immunomodulatory molecule [168,169]. Visfatin can induce
monocytes to produce pro-inﬂammatory cytokines [168]. Likewise,
this adipokine has inﬂammatory and destructive functions promoting
joint damage in patients with RA [169]. Polymorphisms located in
NAMPT (gene that encodes visfatin) were assessed to determine their
potential association with CV disease in patients with RA [170]. In this
context, two genetic variants (NAMPT rs9770242 and NAMPT
rs59744560) related to IR and a pro-atherogenic lipid proﬁle [171,
172], were tested in a cohort of Caucasian RA patients [170]. However,
no signiﬁcant association between these polymorphisms and clinical
CV events or subclinical atherosclerosis was found [170].
3.6. Genes related to lipid metabolism and vitamin D
Endogenous molecules formed because of dyslipidemia, lipid accu-
mulation and oxidative modiﬁcation of lipids retained in the vessel
wall act as danger signals that activate innate immune responses
[173] forming the fatty streak, the earliest visible lesion in thedevelopment of atherosclerosis [55]. Because of that, molecules in-
volved in lipid metabolism are of main importance in the development
of this process and the potential role of gene polymorphisms that inﬂu-
ence the expression of these molecules are of potential relevance in
terms of the CV risk in patients with RA.
Paraoxonase 1 (PON1) is a high-density lipoprotein (HDL)-associat-
ed enzyme that promotes the antioxidant and anti-inﬂammatory prop-
erties of HDL [174–176]. Reduced activity of PON1 has been associated
with CV events in the general population [177] and level variation of
thismolecule ismostly inﬂuenced by the PON1Q192R (rs662) polymor-
phism [178]. However, the involvement of this polymorphism in the de-
velopment of CV disease in RA is controversial [179,180]. Although a
relationship between the mutant PON1 192RR genotype and a de-
creased risk of carotid plaque has been suggested in a small cohort of
Caucasian patients [179], this polymorphism was not associated with
the presence of subclinical atherosclerosis in a large cohort of Spanish
patients with RA [180]. These apparently contradictory resultsmay sug-
gest the implication of other factors related to PON1 activity. In this re-
gard, a recent study has proposed that anti-HDL antibodies may be the
pivotal players to understand the link between PON1 rs662 and CV dis-
ease in RA [181].
Vitamin D receptor (VDR) is an intracellular steroid/thyroid hormone
receptor expressed in almost all tissues and immune cells [182] that ex-
erts its function by binding with its ligand, vitamin D. The vitamin D/
VDR axis affects the transcription of several responsive-genes and also in-
hibits T-helper 1 and T-helper 17 cell responses, while promoting T-
helper 2 and regulatory T cell responses [183]. An association between
VDR gene variants and immune-mediated conditions was disclosed,
being VDRGAT (composed of theminor allele of VDR rs731236, major al-
lele of VDR rs7975232 andminor allele of VDR rs1544410) the risk haplo-
type for coronary artery disease in type-2 diabetes mellitus [184] and
obesity [185]. In keeping with these observations, a potential VDR associ-
ation with atherosclerotic disease was observed in patients with RA
[186]. In this regard, the VDR rs7975232AA genotype was associated
with an increased frequency of carotid plaques in patients with RA
[186]. Similarly, and more importantly, VDR GATG haplotype (who har-
bors the A allele of VDR rs7975232) was more frequently observed in
RA patients with carotid plaques [186].
3.7. Neovascularization genes
It iswell known thatmost pro-inﬂammatory andpro-atherogenicme-
diators enhance neovessel formation whereas most anti-inﬂammatory
and anti-atherogenic mediators inhibit the neovascularization process
[55], a phenomenon of main relevance both in the development and de-
stabilization of atherosclerotic plaques [187,188].
Among pro-angiogenic factors, the vascular endothelial growth fac-
tor (VEGF) has been described as a molecule with pro-inﬂammatory,
pro-atherogenic and pro-angiogenic properties [189,190]. This protein
causes an increase in the plaque growth, [191,192] exerts different ac-
tions in the endothelial cells [193–196] and also stimulates monocytes
[197]. Several polymorphisms within the VEGFA promoter and 5′UTR
region (VEGFA rs2010963 (−634 GNC) and VEGFA rs1570360
(−1154 GNA)) regulate VEGFA expression at the post-transcriptional
level [198]. However, no association of these two VEGFA polymorphisms
with the risk of CV events or the presence of subclinical atherosclerosis
was found in patients with RA [199].
3.8. Nitric oxide synthase (NOS) genes
Asmentioned above, NO is crucial in the development of atheroscle-
rosis. In physiological conditions, NO acts as an anti-inﬂammatory mol-
ecule, maintaining the vascular wall in a quiescent state, also avoiding
cellular proliferation. However, in the presence of inﬂammation or CV
risk factors, the quiescent endothelium can switch to an activated phe-
notype that leads to the secretion of pro-inﬂammatory factors and to
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ﬂammatory condition also leads to a reduction in the release of NO
into the arterialwall, either affecting its synthesis or due to oxidative in-
activation of NO [201,202], which further enhances the inﬂammatory
status and maintains the endothelial activated phenotype [200]. NO is
produced constitutively by the endothelial (eNOS or NOS3), or neuronal
(nNOS or NOS1) synthases, or in higher concentrations by the inducible
(iNOS or NOS2) synthases [203]. Different vascular diseases have been
associated with functional single-nucleotide polymorphisms in NOS2A
and NOS3 [204–206]. In addition, theNOS2A (CCTTT)n repeat variations
have been related to RA susceptibility [207,208]. NOS2A (CCTTT)n poly-
morphism and NOS3 genetic variants (−786 and 298Glu/Asp) do not
infer a direct risk for CV events in patients with RA [209]. Nevertheless,
an association of these genetic variants with CV events was observed in
patients with RA who carried the HLADRB1*0404 allele [209]. These
ﬁndings support the claim that complex gene-gene interactions may
be responsible for the increased risk of CV disease observed in patients
with RA.
3.9. Innate immunity genes
The innate immunity is involved in the atherosclerotic disease pro-
cess, starting from the earliest events of endothelial cell expression of
adhesion molecules, chemokine release and monocyte recruitment to
the complex cellular interactions in the mature lesion [210–212]. Pat-
tern recognition receptors, including Toll-like receptors (TLRs), play
pivotal roles in the development of the atherosclerotic disease
[213–216].
TLRs are single, membrane-spanning, non-catalytic receptors usual-
ly expressed in sentinel cells such as macrophages and dendritic cells
that recognize structurally conserved molecules derived frommicrobes
[217].
TLR4 activation, which depends on bacterial lipopolysaccharides,
promotes the production and release of pro-inﬂammatory cytokines
[218]. This protein can directly interfere with the cholesterol metabo-
lism in macrophages [219]. TLR4 has been detected in human carotid
and coronary atherosclerotic plaques [220,221]. Interestingly, the TLR4
rs4986790 (Asp299Gly) polymorphism was associated with a de-
creased risk of atherosclerosis and acute coronary events in non-
rheumatic individuals [222–224]. However, no relationship between
this genetic variant and the development of CV disease in patients
with RA was observed [225].
The caspase recruitment domain-containing protein 8 (CARD8) is a
member of the cytoplasmic IL-1β regulating protein complex
(inﬂammasome), an assembly of proteins with a substantial role in
modulating adaptive immune responses [226]. This molecule is also in-
volved in pathways leading to activation of caspases or NF-κB in the
context of apoptosis or inﬂammation, respectively. A CARD8 polymor-
phism (rs2043211) that changes cysteine at codon 10 to a premature
termination codon (c.30TNA; p.C10X) was associated with both severi-
ty and a worse disease course in RA [227,228]. However, no association
between CARD8 rs2043211 and the risk of CV disease was found in pa-
tients with RA [229].
3.10. Potential association of other genes with CV disease in RA
A well-characterized enzyme that catalyzes the irreversible reduc-
tion of 5,10-methylene tetrahydrofolate to 5-methyl tetrahydrofolate
(the methyl donor for the conversion of homocysteine to methionine)
is the methylene tetrahydrofolate reductase (MTHFR) [230]. Genetic
variants located in theMTHFR gene (A1298C and C677T) have been re-
lated to decreased MTHFR enzyme activity. This situation leads to
higher homocysteine plasma levels that are associated with an in-
creased risk of CV disease [231–233]. Moreover, an association of the
A1298C polymorphism in the MTHFR gene with susceptibility to RA in
Southern European individuals was reported [234]. The potential roleof these variants in the augmented CV risk observed in RA patients
was also assessed [235]. Although no association between MTHFR
C677T (rs1801133) and CV events or subclinical atherosclerosis was
disclosed [235], the mutant C allele of MTHFR A1298C (rs1801131)
was found to confer an increased risk of CV events (after 5 and 10
years of follow-up) and severe endothelial dysfunction in patients
with RA [235]. In keeping with this observation, we have recently ob-
served a decreased MTHFR expression in RA patients with ischemic
heart disease [236].
The methionine sulfoxide reductase A (MSRA) is a ubiquitous well-
conserved enzyme that carries out the enzymatic reduction of methio-
nine sulfoxide tomethionine. Its function is the repair of oxidative dam-
age to proteins to restore the biological activity [237]. The MSRA gene
has been demonstrated to be involved in the pathogenesis of a variety
of autoimmune disorders [238]. With respect to RA,MSRA rs10903323
polymorphism seems to be implicated in the increased risk to develop
CV events, in particular ischemic heart disease [239].
Ghrelin is a peptide predominantly expressed in the stomach [136]
that has been considered as a relevantMetS-related biomarker that reg-
ulates food intake and growth hormone (GH) expression [240]. In con-
sequence, low levels of this peptide have been observed in obese
individuals [241]. This protein also acts as an anti-inﬂammatory [240,
242] and anti-atherogenic [243] molecule through its expression in im-
mune and vascular cells. Genetic polymorphisms located in the Ghrelin
gene (GHSR), GHSR rs509035 and GHSR rs512692, were associated
with ischemic heart disease in non-rheumatic disease individuals
[244]. These genetic variants along with the GHSR rs2922126 polymor-
phism, which is located in a putative binding site for a transcriptional
factor involved in transcription of matrix metalloproteinase's, were
assessed in patients with RA [245]. However, no association of these
GHSR polymorphisms with CV disease or with subclinical atherosclero-
sis was found in patients with RA [245].
Acid phosphatase locus 1 (ACP1) is a gene that encodes a low molec-
ular weight phosphortyrosine phosphatase implicated in different cell
biological functions [246,247]. This protein has been considered a key
regulator of signaling pathways in receptor-stimulated immune cells
[248], growth factor regulation [249], T-cell development, lymphocyte
activation [250] and in the integrin signaling during cellular adhesion
[248]. ACP1 polymorphisms have been associated with susceptibility
to several human diseases [246,251] and coronary artery disease
[252]. Additionally, the minor allele of ACP1 rs11553742 as well as the
ACP1*C haplotype (integrated by ACP1 rs11553742 minor allele and
ACP1 rs7576247 major allele) was associated with a higher risk of CV
events in RA [253]. However, no relationship between both ACP1
rs10167992 and ACP1 rs3828329 and CV events or subclinical athero-
sclerosis was found in RA [253].
PTPN22 (protein tyrosine phosphatase, non-receptor type 22)
[254–256], TRAF1 (TNF receptor associated factor 1)/C5 (complement
component 5) [257] and STAT4 [258–260] genes are relevant regulators
involved in the pathogenesis of RA. Because of that, the potential associ-
ation of polymorphisms located in these genes and the development of
CV disease in RAwas also assessed [261,262]. However, neither PTPN22
rs2476601 nor STAT4 rs7574865 were found associated with the risk of
CV events or subclinical atherosclerosis in a cohort of RA Spanish pa-
tients of Caucasian ancestry [261]. It was also the case for the TRAF1/
C5 rs10818488 polymorphism [261]. In keeping with these observa-
tions, TRAF1/C5 rs10818488 was not associated with a higher incidence
of mortality due to CV disease in another two Caucasian cohorts [262].
A meta-analysis of subclinical atherosclerosis performed in non-
rheumatic Caucasians described somegenetic variants as signiﬁcant sig-
nals related to both cIMT and presence of carotid plaques [263]. Follow-
ing these ﬁndings, several studies were conducted to determine
whether these polymorphisms could be also implicated in the develop-
ment of CV disease in patients with RA [264]. However, no association
between PIK3CG (phosphatidylinositol-4,5-bisphosphate 3-kinase catalyt-
ic subunit gamma) rs17398575 and EDNRA (endothelin receptor type A)
Table 2
Studies onMetS-related biomarkers, adipokines and biomarkers of endothelial cell activa-
tion and inﬂammation in CV disease in patients with RA.
Molecule Results
IL-6 -Predictor of endothelial dysfunction [291].
-↓ IL-6 serum levels ↓ endothelial cell activation [292].
Ghrelin -↑ Ghrelin serum levels ↓ endothelial cell activation [293].
-No association with cIMT [294].
Adiponectin -↑ Adiponectina serum levels ↑ blood pressure and ↓ glucose
in black and white patients. ↑ adiponectin serum levels
↑favorable lipid proﬁle in black patients. ↑ adiponectin
serum levels ↑endothelial activation in white patients [295].
-↓ Adiponectin serum levels clustered with MetS features
and high-grade inﬂammation [143].
-No association with cIMT [294].
-No association with coronary atherosclerosis [296].
- Adiponectin serum levels are related to ↓ carotid plaque
prevalence in patients with abdominal obesity or clinical absent
joint damage [297].
Leptin -↑ Leptin serum levels ↑ BMI [154].
-No association with cIMT [294].
-Interaction with HOMA-IR index [296].
Leptin/adiponectin
ratio
-Related to MetS factors. Independent marker for CV risk [298].
Resistin -↑ resistin serum levels ↑ CRP and ESR [162,299,300].
-No association with cIMT [294].
-No association with coronary atherosclerosis [296].
-↑ Resistin serum levels ↑ endothelial activation [301].
Visfatin -No association with obesity or MetS [302].
-No association with cIMT [294].
-No association with coronary atherosclerosis [296].
ICAM-1 -No association with cIMT or carotid plaques [307].
ICAM-3 -No association with cIMT or carotid plaques [307].
VCAM-1 -Relationship with cIMT and carotid plaques [291].
P-selectin -No association with cIMT or carotid plaques [307].
E-selectin -No association with cIMT or carotid plaques [307].
Angpt-2 -↑ Angpt-2 serum levels ↑ CV events [308,311].
OPG -↑ OPG serum levels ↑ carotid plaques [314,315].
-↑ OPG serum levels ↑ endothelial cell activation [315].
-↑ OPG serum levels ↑ CV events [316].
TRAIL -↓TRAIL serum levels ↑ HF [325].
ADMA -↑ADMA serum levels are related to markers of active
inﬂammation and oxidative stress [335].
SDMA -↑SDMA serum levels ↑IS and disease activity score [326].
-No association with traditional CV disease risk factors
and markers of inﬂammation [340].
MetS: metabolic syndrome; CV: cardiovascular; RA: rheumatoid arthritis; IL: interleukin;
cIMT: carotid intima–media thickness; BMI: body mass index; HOMA-IR: homeostatic
model assessment-insulin resistance; CRP: C-Reactive protein; ESR: erythrocyte sedimen-
tation rate; ICAM: intercellular adhesion molecule; VCAM: vascular endothelial adhesion
molecule; Angpt: angiopoietin; OPG: Osteoprotegerin; TRAIL: tumor necrosis factor-relat-
ed apoptosis-inducing ligand; HF: heart failure; ADMA: asymmetric dimethylarginine;
SDMA: Symmetric dimethylarginine; IS: insulin sensitivity.
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rosis in RA was observed [264].
In line with the above, a large-scale study identiﬁed several genetic
factors as relevant polymorphisms involved in the development of cor-
onary artery disease in the general population [265]. Based on these
ﬁndings, several studies addressed the potential role of these polymor-
phisms in the development of CV disease in RA [264,266–271]. Interest-
ingly, patients with RA carrying the minor allele of PSRC1 (proline/
serine-rich coiled-coil 1)-CELSR2 (cadherin EGF LAG seven-pass G-type re-
ceptor 2)-SORT1 (sortilin 1) rs599839 showed a higher risk of endotheli-
al dysfunction [268] whereas the ZC3HC1 (zinc ﬁnger C3HC-type
containing 1) rs11556924T mutant allele was associated with increased
cIMT values in patients with RA [267]. Also, theMIA3 (melanoma inhib-
itory activity family member 3) rs17465637 [269] and ZNF259-APOA5-
A4-C3-A1 rs964184 (zinc ﬁnger protein 259-apolipoprotein A-V-IV-C-III-
A-I) [271] were associated with the development of CV events in
Spanish RA patients but not in UK individuals with RA [266]. In contrast,
CXCL12 (C-X-C motif chemokine ligand 12) rs1746048 was proposed to
be a genetic variant involved in the CV risk of patients with RA from
UK [266]. However, no association of this polymorphismwith CV events
was observed in a large series of Spanish patients with RA [270].
3.11. New strategies for the assessment of the genetic inﬂuence of CV
disease in RA: high-throughput genotyping techniques
Unlike candidate gene strategy, in high-density polymorphism ar-
rays, hundreds of thousands of probes are arrayed on a small chip
allowing for many genetic variants to be interrogated simultaneously.
Among them, Immunochip and Genome-Wide Association Studies
(GWAS) are large-scale approaches used in the genetic characterization
of immune-mediated diseases [272,273]. Immunochip allows a dense
analysis of 196,524 single-nucleotide polymorphisms, rare variants,
and insertion/deletion polymorphisms, located within 186 known sus-
ceptibility loci for autoimmune and inﬂammatory disorders [274]. Oth-
erwise, GWAS approach is a free-hypothesis genetic method [275] in
which hundreds of thousands of single-nucleotide polymorphisms can
be analyzed across the whole genome [276].
The use of these techniques in patients with RA has substantially in-
creased the number of established genetic risk factors related to this pa-
thology [90,257,277,278]. However, information speciﬁcally focused on
CV disease in RA is not available yet. In this regard, the ﬁrst GWAS and
Immunochip studies for CV outcome in RA are underway in a cohort
of Spanish patients. Of potential relevance may be the results derived
from the assessment of a large series of RA patients in whom informa-
tion on cIMT and carotid plaques is also available. Data generated in
these studies may help to improve our understanding of the genetic
bases of this pathology and provide new candidate genetic markers of
CV disease in RA.
4. MetS-related biomarkers, adipokines and biomarkers of
endothelial cell activation and inﬂammation and CV disease in RA
MetS represents a cluster of CV risk factors, such as obesity, elevated
triglycerides, low levels of HDL-cholesterol, high systolic and diastolic
blood pressure and elevated fasting glucose [279] that triggers IR and in-
creased visceral adiposity [280]. This entity has received great attention
in the last years due to its contribution to the burden of CV morbidity
and mortality [281–283] and its high prevalence in patients with in-
ﬂammatory rheumatic diseases [282] such as RA [31,32,139,284,285].
The adipose tissue is not only a passive tissue but it is also considered
a dynamic organ that releases adipokines [31,137,285,286] and some
pro-inﬂammatory cytokines. In this regard, visceral fat accumulation as-
sociatedwith adipokinedysregulation affects subclinical atherosclerosis
[287], being particularly related to atherosclerotic plaque development
and disruption. Additionally, the release of pro-inﬂammatory cytokines
together with MetS factors leads to endothelial cell activation and,consequently, to the expression of endothelial adhesion molecules
that recruit inﬂammatory cells to the vascular wall, which generates re-
active oxygen species [200].
Much effort has recently been focused on the potential inﬂuence of
MetS-related biomarkers, adipokines and biomarkers of endothelial
cell activation and inﬂammation in the development of CV disease in
patients with RA. In this sense, results of these studies indicate these
molecules as relevant biomarkers of CV outcome in RA. A review of
these studies is discussed below. Furthermore, a summary is shown in
Table 2.
4.1. MetS-related biomarkers
Asmentioned before, IL-6 is a pleiotropic cytokinewith a crucial role
in pro-inﬂammatory responses. However, it is important to highlight
that this protein also plays a direct role inmediating IR [288]. Speciﬁcal-
ly, IL-6 acts by inhibiting insulin receptor signal transduction and insulin
action [288]. In this regard, elevated IL-6 serum concentration has been
proposed as an essential factor related to pathologies associatedwith IR
[289,290]. Based on this information, the potential inﬂuence of IL-6
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also been assessed. In this respect, Dessein et al. have described that
IL-6 is independently predictive of endothelial dysfunction [291] and,
therefore, a reduction in its serum levels leads to decreased endothelial
cell activation in patients with RA [292].
Since ghrelin is an anti-inﬂammatory molecule and low levels of
ghrelin may be associated with obesity [241], several studies have been
focused on the potential role of this molecule in the development of CV
events and subclinical atherosclerosis in RA. In this regard, in a series of
RA patients with severe disease undergoing anti-TNF-α inﬂiximab ther-
apy a rapid increase of serum ghrelin levels was observed following a
single administration of this biologic agent [293]. Additionally, increased
ghrelin circulating concentration was associated with decreased endo-
thelial cell activation [293]. However, no association between serum
levels of this molecule and cIMT values was found [294].
4.2. Adipokines
Dessein et al. examined the independent relationship of the total
and high molecular weight concentrations of adiponectin with cardio-
metabolic risk factors and surrogate markers of enhanced early athero-
genesis in black and white patients with RA [295]. Both populations ex-
hibited a positive adiponectin–blood pressure correlation and an
inverse adiponectin–glucose concentration association [295]. However,
whereas a positive adiponectin-favorable lipid proﬁle interaction was
found in black RA patients, a positive adiponectin–endothelial activa-
tion association in white RA participants was described [295]. On the
other hand, in a study performed in RA patients undergoing anti-TNF-
α inﬂiximab therapy, high-grade inﬂammation was independently
and negatively correlated with adiponectin circulating concentration
whereas low adiponectin serum levels clustered with MetS features
such as dyslipidemia and high plasma glucose levels [143]. Although
no association between adiponectin circulating concentration and
both cIMT [294] and coronary artery calciﬁcation [296] has been dem-
onstrated, an independent relationship between total and highmolecu-
lar weight adiponectin concentration and reduced plaque prevalence in
RA patients with abdominal obesity or clinical absent joint damage has
been described [297].
Circulating levels of leptin have been implicated in the development
of CV events in RA. In this context, a positive correlation between body
mass index and leptin serum levels in patients undergoing anti-TNF-α
inﬂiximab therapy was reported [154]. Moreover, a signiﬁcant interac-
tion between leptin circulating levels and homeostatic model assess-
ment (HOMA)-IR index was described [296]. However, no association
between leptin circulating levels and cIMT was found [294].
The role of leptin/adiponectin has been related to MetS risk factors
and this ratio has been proposed to be an independent factor for the
prediction of CV risk in RA [298].
A positive correlation of CRP and ESRwith Resistin serum levels was
found in patients with RA [162,299,300]. Because of that, it could be
plausible to think that resistin concentrations may play a relevant role
in the augmented CV risk observed in RA. In keeping with that, a rela-
tionship between Resistin circulating concentration and endothelial
cell activation was described [301]. However, no association of resistin
concentrations with cIMT [294] or coronary artery calciﬁcation [296]
has been demonstrated.
No association between circulating visfatin concentrations and cIMT
[294] and coronary artery calciﬁcationwas found [296]. Similarly, circu-
lating visfatin levels were unrelated to disease activity, adiposity, and
MetS or CV mortality in RA patients undergoing anti-TNF-α therapy
[302].
4.3. Biomarkers of endothelial cell activation and inﬂammation
Endothelial cell adhesion molecules such as intercellular adhesion
molecule (ICAM)-1, ICAM-3, vascular endothelial adhesion molecule(VCAM)-1, P-selectin and E-selectin are biomarkers of endothelial acti-
vation and atherosclerosis [303]. Variations in the concentration of sol-
uble endothelial cell adhesion molecules have been found directly
associated with the development of CV disease [304,305]. Regarding
RA, following a single anti-TNF-α inﬂiximab infusion a reduction of sol-
uble (s)ICAM-1, sICAM-3, sVCAM-1, sE-selectin, and sP-selectin levels
was observed in patients with severe disease undergoing period treat-
mentwith this biologic agent [306]. However, whereas elevated soluble
levels of VCAM-1 were found related to cIMT and carotid plaques [291],
no association between levels of ICAM-1, ICAM-3, P-selectin, E-selectin
with cIMT or carotid plaques was found [307].
Angiopoietin-2 (Angpt-2) is a pro-inﬂammatorymarker [136] of en-
dothelial cell activation required for the formation of blood vessels [308]
that participates in the communication of endothelial cells with the sur-
rounding mesenchyme to establish stable cellular interactions [309]. A
role of this protein as amediator of angiogenesis aswell as the inﬂuence
of Angpt-2 on the regulation of endothelial integrity has been postulat-
ed [310]. A study performed in recent onset RA revealed that patients
with CV disease exhibited higher Angpt-2 serum levels than thosewith-
out this complication [308]. A correlation between age at the time of dis-
ease onset and Angpt-2 was observed in Spanish RA patients. Angpt-2
serum levels also correlated positively with extra-articular disease.
Moreover, Angpt-2 levels were higher in RA patients with CV disease
than in RA patients without CV complications [311].
OPG is a protein with a pivotal role in bone remodeling that has also
been implicated in the pathophysiology of RA [312,313]. This molecule
has been proposed as a potential biomarker of CV risk since increased
levels were associated with CV disease in non-rheumatic individuals
[69]. An association between elevated OPG serum levels and both in-
creased prevalence of carotid artery plaque [314,315] and enhanced en-
dothelial cell activation [315] has been documented in patients with RA.
Additionally, a relationship between OPG serum concentrations and the
prevalence of CV events in RA has also been disclosed [316].
OPG acts as a soluble neutralizing receptor for a member of the TNF
superfamily, TNF-related apoptosis-inducing ligand (TRAIL). This is a
molecule that exhibits anti-inﬂammatory and anti-atherosclerotic
properties [317–319]. TRAIL can be expressed as a trans-membrane
protein or secreted as a soluble molecule [320]. Low TRAIL circulating
concentration has been associated with poor outcome in patients with
heart disease including those with acute myocardial infarction and
heart failure [321–323]. Regarding RA, TRAIL not only participates in
its pathophysiology [324] but its serum concentrations are alsomarked-
ly reduced and associated with the development of heart failure [325].
Dimethylarginines are endogenous guanidine-substituted analogues
of l-arginine, the precursor of NO, which are naturally liberated in biolog-
ical ﬂuids following proteolysis [326]. Among them, asymmetric
dimethylarginine (ADMA) has been proposed as a biomarker for
endothelial dysfunction and a CV risk factor [327,328]. Furthermore ele-
vated ADMA serum levels have been associated with hypertension
[329], hypertriglyceridemia [330], hypercholesterolemia [331], diabetes
mellitus [332], IR [333] and with inﬂammatory diseases such as RA
[334]. A correlation between elevated serum levels of ADMA andmarkers
of active inﬂammation and oxidative stress has been observed in RA pa-
tients [335]. On the other hand, symmetric dimethylarginine (SDMA),
the structural counterpart of ADMA, affects vascular haemostasis [336]
and has been described as an independent CV risk factor in non-
rheumatic individuals [337–339]. A positive relationship between SDMA
serum levels and both insulin sensitivity and disease activity score was
described in RA patients [326]. However, a lack of association between
serum concentrations of this molecule and traditional CV disease risk fac-
tors and markers of systemic inﬂammation in RA was disclosed [340].
5. Current situation and future perspectives
RAhas an impact on several physical andmental functions and inﬂu-
ences activities of daily living and participation in social situations. Since
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this pathology leads to a considerable burden on society in terms of
morbidity, long-term disability, direct (both medical and non-
medical) and indirect (derived from the impact on productivity) costs
[342,343]. Over the past decade, research on mortality in RA has gained
momentum. These studies have consistently demonstrated an in-
creased mortality in patients with RA when compared with expected
rates in the general population [344–350]. The standardized mortality
ratio in these patients varied from 1.28 to 2.98 and has remained un-
changed over the past two to three decades [345]. A number of investi-
gators have examined the underlying causes for the observed excess
mortality in RA and they have demonstrated that this is largely attribut-
able to CV disease [1–4,6,7,9,351].
Current CV risk stratiﬁcation in RA is based on strategies used for the
general population. In this regard, based on a pool of datasets from 12
European cohort studies, mainly carried out in general population set-
tings, European experts performed the systematic coronary risk evalua-
tion (SCORE) project to develop a risk scoring system to use in the
clinical management of CV risk in the European clinical practice [352].
On the other hand, the FraminghamRisk Score is the gender-speciﬁc al-
gorithmmore commonly used in North-America to estimate the CV risk
of an individual [353].
The updated version of the SCORE and the Framingham score esti-
mate the absolute 10-year risk for fatal CV disease events and any CV
disease event, respectively [352,354]. Thresholds of a SCORE of 5% or
more and a Framingham score of 20% or more are considered indica-
tions for intensiﬁed risk factor management mostly with CV drugs and
particularly statins [352,353]. Regrettably, adequate stratiﬁcation of
the CV disease risk in patients with RA is still far from being completely
established. Classic risk algorithms, mainly based on traditional CV risk
factors, used to estimate the CV disease risk in the general population
underestimate incident CV event rates in patients with RA [355]. More
importantly, reports showing RA patients who did not reach values to
be considered as having high CV disease risk according to these CV
risk estimates, such as the SCORE modiﬁed according to the European
League Against Rheumatism (EULAR) recommendations [356], that ex-
perienced CV complications, mainly ischemic heart disease, have been
reported [20]. In addition, several studies have conﬁrmed that manyFig. 1. Proposed CV disease risk assessment in patients with RA. To perform an adequate CV st
clinical and demographic data (age, sex, disease duration, RF status, presence/absence of anti
drugs). 2) A carotid US evaluation to determine cIMT values and the presence/absence of caro
identify genetic markers (by microarrays) and serum to assess biomarker circulating levels (b
anti-CCP: anti-cyclic citrullinated peptide antibodies; US: ultrasonography; cIMT: carotid intimpatients with RA included in the category ofmoderate CV risk according
to CV disease risk algorithms have carotid plaques [39,40] and, there-
fore, should be considered as very high CV disease risk patients.
Therefore, the search for additional tools that may help to identify
high-CV disease risk patients, who may beneﬁt from active therapy to
prevent CV events, is needed. It may be of major importance in RA pa-
tients that are not included in the categories of high or very high CV
risk according to the classic risk assessment algorithms.
Non-invasive surrogatemarkers that can be used in the daily clinical
practice have been found useful to identify RA at risk of CV events. Both
abnormally high values of cIMT as well as the presence of carotid
plaques were found as excellent predictors of future CV events in RA
[22,23].
Since CV disease in RA is the result of a complex interaction between
classic CV risk factors a genetic component and inﬂammation, the
search for additional markers of CV is ofmajor importance. As discussed
throughout the review, several genetic factors exert inﬂuence with dif-
ferent effects on the risk of CV disease in RA [19,24,25,36,48–51,56–60,
76,77,92,103,108,118,119,179,181,186,209,235,236,239,253,266–268,
271]. In consequence, an important step forwardmay be to create a con-
sistent set of geneticmarkers thatwould eventually be introduced into a
standardized microarray and may be used as a guide for the CV disease
risk stratiﬁcation of patients with RA. Therefore, commercial genetic
chips would be used as an additional tool to predict each RA patient’s
probability of developing CV disease based on the genetic background.
Variations in serum levels of several MetS-related biomarkers,
adipokines and biomarkers of endothelial cell activation and inﬂamma-
tion appear to be implicated in the augmented CV risk observed in RA
patients [143,154,162,291–293,295–301,307,308,311,314–316,325,
335,336]. In this context, the information derived from the studies on
biomarkers detailed in this review would be used to design a speciﬁc
commercial multiplex assay. This technique would allow us to test si-
multaneously the serum levels of all biomarkers related to the develop-
ment of CV disease offering a better CV risk characterization of each RA
patient diagnosed.
In summary, current CVdisease risk assessment algorithms underes-
timate the actual CV risk in RA. Accordingly, an adequate CV disease
stratiﬁcation in these patients would include the following stepsratiﬁcation in patients with RA, the following steps would be performed: 1) Collection of
-CCP, traditional CV disease risk factors and intake of non-steroidal or anti-inﬂammatory
tid plaques. 3) Blood sample collection to obtain DNA and serum. DNA would be used to
y multiplex assays). CV: cardiovascular; RA: rheumatoid arthritis; RF: rheumatoid factor;
a–media thickness.
1024 R. López-Mejías et al. / Autoimmunity Reviews 15 (2016) 1013–1030(Fig. 1): 1) Collection of clinical and demographical data (including in-
formation on age, sex, disease duration, rheumatoid factor status,
presence/absence of anti-CCP, traditional CV risk factors and intake of
non-steroidal or anti-inﬂammatory drugs); 2) A non-invasive carotid
ultrasound assessment to determine cIMT values as well as the pres-
ence/absence of carotid plaques; 3) Blood sample collection to obtain
both deoxyribonucleic-acid (DNA) and serum of each patient with RA.
Following this procedure, DNA would be used to evaluate the genetic
background of patients by genetic microarrays. On the other hand, mul-
tiplex assayswould be performed on serum samples to assess the circu-
lating levels of MetS-related biomarkers, adipokines and biomarkers of
endothelial cell activation and inﬂammation. The combined effort of
these 3 areas would lead us to a better CV disease risk stratiﬁcation in
RA. It would allow us to determine the best therapeutic approach for
each individual patient, preventing or delaying the onset of CV events.Take-home messages
• Current CV algorithms underestimate the actual CV risk of patients
with RA.
• Carotid US is useful in the CV risk stratiﬁcation of patients with RA.
• Genetic and serological biomarkersmay help to identify RApatients at
CV disease risk.
• Efforts focused on CV risk development calculators including new
markers are underway.
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